1. Calculate your BMI
BMI (Body Mass Index) is the most widely used screening number for weight-loss medication eligibility. It’s not a perfect measure of health, but it provides the starting baseline for clinical evaluation.
Quick BMI Calculator
2. Standard eligibility criteria
International obesity-treatment guidelines (FDA, EMA, JASSO) generally support pharmacological weight-loss treatment under one of two conditions:
Standard criteria — international guidelines
If you meet either criterion, you’re likely a candidate from a BMI standpoint. The physician will still need to confirm there are no contraindications.
3. Comorbidities that lower the threshold
If your BMI is 27-29.9, you may still qualify for Mounjaro if you have at least one of the following weight-related conditions:
| Condition | What counts |
|---|---|
| Hypertension | BP ≥ 130/80 or on antihypertensive medication |
| Type 2 diabetes | Diagnosed T2DM, including pre-diabetes (HbA1c 5.7-6.4%) |
| Dyslipidemia | High cholesterol, high triglycerides, or on lipid-lowering medication |
| Sleep apnea | Diagnosed obstructive sleep apnea (OSA), particularly moderate-to-severe |
| Fatty liver (NAFLD/MASLD) | Imaging-confirmed or biopsy-confirmed liver steatosis |
| PCOS | Polycystic ovary syndrome with insulin-resistance features |
| Cardiovascular disease | Established CAD, stroke history, or peripheral artery disease |
| Knee/joint pain from weight | Symptomatic osteoarthritis worsened by excess weight |
Most clinics accept these conditions based on patient-reported history, though documentation (lab results, imaging reports) strengthens the case.
4. Asian-Pacific BMI cutoffs
One of the most important nuances for international patients: Asian populations develop obesity-related complications at lower BMIs than Western populations. A Japanese, Vietnamese, Thai, or Indonesian patient with BMI 27 may have a cardiometabolic profile equivalent to a Western patient at BMI 30.
The WHO and Asia-Pacific guidelines have adjusted thresholds accordingly:
| Category | Western (WHO standard) | Asian-Pacific |
|---|---|---|
| Normal | 18.5 – 24.9 | 18.5 – 22.9 |
| Overweight | 25 – 29.9 | 23 – 24.9 |
| Obesity Class I | 30 – 34.9 | 25 – 29.9 |
| Obesity Class II | 35 – 39.9 | 30+ |
For Asian-Pacific patients, BMI 25+ with comorbidities or BMI 27.5+ without comorbidities is often sufficient for pharmacological weight-loss treatment under regional guidelines. JASSO (Japan Society for the Study of Obesity) uses similar thresholds for medical interventions. Discuss with your prescribing physician how Asian-specific criteria apply to your case.
5. Who should NOT take Mounjaro
Even if you meet BMI criteria, certain conditions absolutely contraindicate Mounjaro use:
⚠ Absolute contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) — based on rodent studies showing thyroid C-cell tumors; causation in humans not established but the warning is preserved
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning pregnancy — discontinue Mounjaro at least 2 months before trying to conceive
- Breastfeeding — not recommended; tirzepatide may be transferred via milk
- Known allergy to tirzepatide or any inactive ingredient
- Severe gastrointestinal disease — particularly diabetic gastroparesis or severe gastroparesis from other causes
- History of acute pancreatitis — relative contraindication; some patients may still be candidates with caution
- Type 1 diabetes — Mounjaro is not indicated for type 1 diabetes and may worsen hypoglycemia risk
Use with caution
The following situations require careful evaluation and aren’t outright contraindications, but warrant extra discussion:
- Diabetic retinopathy (rapid blood-sugar improvement can temporarily worsen)
- Known gallbladder disease (rapid weight loss increases gallstone risk)
- Current use of insulin or sulfonylureas (hypoglycemia risk; dose adjustments needed)
- Severe kidney disease (limited data; lower starting dose may be appropriate)
- Severe liver impairment (limited data)
- BMI under the threshold but seeking to lose “a few kg” — generally not appropriate medical use
6. What if I’m below the BMI cutoff?
If your BMI is below 27 (or below 23-25 in Asian populations) and you’re looking to lose modest weight, Mounjaro is generally not appropriate. The risk-benefit balance doesn’t favor prescription medication for cosmetic-range weight loss. Reputable clinics will decline to prescribe in these cases — and you should be skeptical of clinics that don’t.
Better alternatives at lower BMIs:
- Nutrition consultation — a registered dietitian can identify what’s blocking your progress without medication
- Structured exercise programs — including resistance training, which improves body composition without dropping BMI dramatically
- Behavioral coaching — for emotional eating, stress eating, or pattern habits
- Sleep evaluation — poor sleep is a hidden driver of weight gain
- Hormonal evaluation — thyroid, cortisol, insulin resistance markers can all influence weight
If after evaluation you genuinely have a metabolic health issue that warrants pharmacological intervention even at lower BMI, a thorough specialist consultation can determine appropriateness on a case-by-case basis.
7. What happens at the consultation
A well-run online weight-loss consultation typically covers:
- Medical history review — current medications, allergies, surgical history, chronic conditions
- Weight history — when weight gain started, prior attempts, family history
- Comorbidity screening — blood pressure, blood sugar, lipid panel if available, sleep quality, joint pain
- Contraindication check — thyroid history (personal and family), pregnancy status, pancreatitis history, GI disease
- Goals discussion — what you want to achieve, timeline expectations, lifestyle factors
- Treatment plan — if appropriate, dose, escalation schedule, monitoring approach
- Lifestyle integration — nutrition guidance, activity recommendations, follow-up cadence
If the doctor doesn’t ask about thyroid history or doesn’t mention lifestyle support, that’s a red flag about clinic quality. Treatment of obesity is medical care — not e-commerce.
If you have any of the following, bring documentation: recent BMI/weight, blood pressure readings, recent lab results (cholesterol, HbA1c, liver enzymes), list of current medications, family medical history. The more information you provide, the more accurate the assessment.
8. FAQ
What BMI is needed for Mounjaro?
BMI 30+ alone, or BMI 27+ with at least one weight-related comorbidity. For Asian-Pacific patients, lower thresholds may apply: BMI 27.5+ for obesity, BMI 23+ as overweight.
Can I take Mounjaro if my BMI is below 27?
Standard guidelines do not support Mounjaro prescription purely for weight loss below BMI 27. Asian-Pacific guidelines suggest lower thresholds may apply. A reputable physician will evaluate your individual case — including comorbidities and Asian-specific BMI standards — rather than applying a strict number.
Who should NOT take Mounjaro?
Contraindicated for patients with personal/family history of medullary thyroid carcinoma (MTC), MEN 2 syndrome, pregnancy/breastfeeding, severe gastroparesis, history of severe pancreatitis, type 1 diabetes, and known allergy to tirzepatide.
Do BMI rules apply differently to Asians?
Yes. Asian-Pacific guidelines (used by JASSO, WHO regional offices) recognize lower BMI thresholds: overweight ≥23, obesity ≥25. This reflects evidence that Asian populations develop metabolic complications at lower BMIs than Western populations.
I’m not sure if I have a comorbidity — what counts?
Conditions count if they are diagnosed by a physician or evidenced by lab/imaging results. Self-diagnosed conditions don’t carry weight. The most common qualifying comorbidities are high blood pressure (≥130/80 or on medication), pre-diabetes (HbA1c 5.7-6.4%) or T2DM, high cholesterol, sleep apnea, and fatty liver.
Will I be denied if I’m close but not over the threshold?
It depends on the clinic and individual case. Some clinics apply strict cutoffs; others evaluate the overall risk-benefit profile. If your BMI is 26 with multiple risk factors (Asian heritage, family history of diabetes, sedentary work), a thorough physician may still recommend treatment. If your BMI is 25 with no risk factors, expect to be declined for medication and offered lifestyle support instead.
Sources & further reading
- WHO Expert Consultation — Appropriate body-mass index for Asian populations, The Lancet 2004
- Japan Society for the Study of Obesity (JASSO) — Obesity treatment guidelines
- US FDA — Mounjaro prescribing information and indications
- Eli Lilly — Mounjaro patient eligibility criteria
- American College of Cardiology / American Heart Association — Obesity management guidelines